Baird served as lead manager on this offering
AboutLeap Therapeutics, Inc. (“Leap”) (NASDAQ-GM:LPTX) recently completed an underwritten public offering of 25,875,000 shares of its common stock and pre-funded warrants, which included the exercise in full by the underwriters of their option to purchase an additional 3,375,000 shares of common stock. The gross proceeds to Leap from the offering are expected to be approximately $51.8 million.
Leap is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic and prostate cancers. Leap has formed a partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia and New Zealand. Leap Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
- June 2020
- Leap Therapeutics, Inc.
- Target Location
- North America